



07<sup>th</sup> November, 2024

**To,  
The Corporate Relations Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001.**

Dear Sir/Madam,

**Sub: Intimation of Board Meeting under Regulation 29 of SEBI (LODR) Regulations, 2015 and all other applicable regulations.**

**Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH**

\*\*\*\*\*

This is to inform you that a meeting of Board of Directors of the company will be held on Thursday, November 14, 2024, inter alia, to consider the Un-audited financial results of the Company for the Second quarter ended on September 30, 2024 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

In continuation to our earlier intimation of closure of trading window, we would like to inform that the trading window of the Company for all the designated persons and their immediate relatives will remain closed till November 16, 2024, which is 48 hours after the said Board Meeting.

This is for your information and records.

Thanking you

Yours faithfully,

**For Oxygenta Pharmaceutical Limited**

**Name: Sai Sudhakar Vankineni**

Designation: Managing Director

DIN.: 00733001

---

**OXYGENTA PHARMACEUTICAL LIMITED** (Formerly known as S.S ORGANICS LIMITED)

(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.

Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038